https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / J Immunother 2012 Jan;35(1):54-65
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / J Immunother 2012 Jan;35(1):54-652012-01-01 00:00:002023-03-07 13:05:51A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / Urologe A 2012 Jan;51(1):44-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / Urologe A 2012 Jan;51(1):44-92012-01-01 00:00:002019-02-15 08:52:47[Prostate carcinoma: vaccination as a new option for treatment]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / Methods Mol. Biol. 2012;797:177-204
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / Methods Mol. Biol. 2012;797:177-2042012-01-01 00:00:002021-11-15 16:57:22Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-12-06 / Arch. Immunol. Ther. Exp. (Warsz.) 2012 Feb;60(1):69-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-12-06 / Arch. Immunol. Ther. Exp. (Warsz.) 2012 Feb;60(1):69-772011-12-06 00:00:002019-02-15 08:45:32Immunotherapy of lung adenocarcinoma patient with Peptide-pulsed dendritic cells: a case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-12-01 / Curr. Opin. Neurol. 2011 Dec;24(6):641-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-12-01 / Curr. Opin. Neurol. 2011 Dec;24(6):641-72011-12-01 00:00:002019-02-15 08:46:36Immunotherapy for glioma: getting closer to the clinical arena?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-30 / Clin. Dev. Immunol. 2011;2011:842849
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-30 / Clin. Dev. Immunol. 2011;2011:8428492011-11-30 00:00:002011-11-30 00:00:00The roles of tumor-derived exosomes in cancer pathogenesis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-30 / Leuk. Res. 2012 May;36(5):634-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-30 / Leuk. Res. 2012 May;36(5):634-452011-11-30 00:00:002011-11-30 00:00:00Anti-leukemic activity of Newcastle disease virus strains AF2240 and V4-UPM in murine myelomonocytic leukemia in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-26 / Vaccine 2012 Jun;30(29):4394-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-26 / Vaccine 2012 Jun;30(29):4394-72011-11-26 00:00:002019-02-15 08:52:45Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-23 / Int. J. Oncol. 2012 Mar;40(3):764-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-23 / Int. J. Oncol. 2012 Mar;40(3):764-722011-11-23 00:00:002019-02-15 08:46:36Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-16 / Cancer Immunol. Immunother. 2012 Jun;61(6):865-79
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-16 / Cancer Immunol. Immunother. 2012 Jun;61(6):865-792011-11-16 00:00:002019-02-15 08:45:53Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria
